Compare CNXU & IAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNXU | IAE |
|---|---|---|
| Founded | 2022 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.7M | 97.0M |
| IPO Year | 2025 | N/A |
| Metric | CNXU | IAE |
|---|---|---|
| Price | $3.32 | $8.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 163.1K | 34.1K |
| Earning Date | 02-03-2027 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.21% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.60 | $7.04 |
| 52 Week High | $13.66 | $9.27 |
| Indicator | CNXU | IAE |
|---|---|---|
| Relative Strength Index (RSI) | 29.51 | 50.38 |
| Support Level | N/A | $8.79 |
| Resistance Level | $5.47 | $8.90 |
| Average True Range (ATR) | 0.41 | 0.17 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 2.97 | 49.18 |
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.